Exactmer co-authored a peer-reviewed paper published in ACS Organic Process Research & Development demonstrating membrane-based purification for the synthesis of oligonucleotides, peptides, and other fragments using an Exact-10™ membrane for upstream synthesis and fragment rejection, an Exact-01™ for solvent recovery, and an Exact-20™ for downstream TFF purification.
Published
Signal category
Research & Knowledge
Quote
“A new peer reviewed paper published in ACS Organic Process Research & Development, co authored by Exactmer's Adam Oxley in collaboration with Queen Mary University of London and Eli Lilly and Company, shows membrane based purification is a credible alternative for the synthesis of oligonucleotides, peptides and other fragments.”
— Exactmer team
Company
Exactmer
Manufacturing exact polymer pharmaceuticals by Nanostar Sieving; bringing advanced therapeutics to all patients in need.
- Industry
- Pharmaceutical Manufacturing
- Location
- Yew Tree Avenue, GB
- Company size
- 22 employees
Exactmer owns the Nanostar Sieving technology platform. This employs iterative, liquid-phase chemistry coupled to membrane purification, to create polymers of outstanding purity. Exactmer is currently advancing the production of oligonucleotides at scale, bringing these advanced therapeutics to all patients in need. Nanostar Sieving can also produce unimolecular polyethylene glycols (PEGs), including a disruptive new suite of multi-functional 'PEGabets', with handles for conjugation along the polymer backbone; ideal linkers molecules for Antibody Drug Conjugates.
Founded 2017